RPg Family Wealth Advisory LLC Purchases 176,998 Shares of Amneal Pharmaceuticals, Inc. $AMRX

RPg Family Wealth Advisory LLC lifted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 88.5% during the 2nd quarter, HoldingsChannel reports. The firm owned 377,090 shares of the company’s stock after buying an additional 176,998 shares during the period. RPg Family Wealth Advisory LLC’s holdings in Amneal Pharmaceuticals were worth $6,527,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of AMRX. Kemnay Advisory Services Inc. purchased a new position in Amneal Pharmaceuticals in the fourth quarter worth $26,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Amneal Pharmaceuticals during the second quarter valued at approximately $29,000. Federated Hermes Inc. boosted its position in Amneal Pharmaceuticals by 1,680.6% during the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after buying an additional 2,168 shares during the period. Comerica Bank grew its holdings in Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after acquiring an additional 1,957 shares during the last quarter. Finally, Transamerica Financial Advisors LLC increased its position in shares of Amneal Pharmaceuticals by 541.9% in the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after acquiring an additional 2,460 shares during the period. 31.82% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on AMRX shares. UBS Group upped their price objective on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Weiss Ratings upgraded Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. Zacks Research raised Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. Barclays increased their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $22.00 price objective on shares of Amneal Pharmaceuticals in a research report on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to MarketBeat, Amneal Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $19.00.

Insiders Place Their Bets

In other news, EVP Nikita Shah sold 146,403 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the completion of the sale, the executive vice president owned 253,390 shares of the company’s stock, valued at $4,436,858.90. This represents a 36.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director John Kiely sold 50,000 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $17.64, for a total transaction of $882,000.00. Following the completion of the transaction, the director owned 210,252 shares in the company, valued at $3,708,845.28. The trade was a 19.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 413,016 shares of company stock valued at $7,216,567. Insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Price Performance

AMRX stock opened at $17.54 on Monday. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The firm has a 50 day moving average price of $17.68 and a 200-day moving average price of $14.86. Amneal Pharmaceuticals, Inc. has a 52-week low of $9.32 and a 52-week high of $19.26. The firm has a market capitalization of $5.60 billion, a price-to-earnings ratio of 35.80 and a beta of 1.27.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.06. The business had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.94 EPS for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.